Skip to content

Lyonna F Parise

3 papers in the library · 76 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Transcriptional profiles of antidepressant resistance across the corticolimbic pathway of chronically stressed mice.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 1, 2026 Trevonn M Gyles, Eric M Parise, Molly S Estill et al.

Treatment-resistant depression (TRD), defined by unsuccessful response to multiple antidepressants, affects approximately one-third of individuals with major depressive disorder, yet its underlying molecular mechanisms remain poorly understood. Here, we developed a preclinical model of TRD in which mice exposed to chronic social defeat stress were sequentially treated with fluoxetine (FLX) and...

Prophylactic Ketamine: Current Knowledge and Future Directions.

Biological Psychiatry March 28, 2025 Astrid M Cardona-Acosta, Lyonna F Parise, Carlos A. Bolaños-Guzmán et al. 2 citations

The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been increasing, while current treatment approaches are limited. As a result, researchers are exploring alternative treatments that include ketamine as a prophylactic against these disorders. This review provides an overview of the current knowledge on the use...

Structural pharmacology and therapeutic potential of 5-methoxytryptamines.

Nature June 1, 2024 Audrey L Warren, David Lankri, Michael J. Cunningham et al. 74 citations

Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders1-3. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT2A (ref. 4). However, 5-HT1A also plays a part in the behavioural effects of tryptamine...